In a report released on May 14, David Evans from Kepler Capital maintained a Sell rating on Alcon (ALC – Research Report), with a price target of CHF62.00. The company’s shares closed yesterday at $89.97.
Evans covers the Healthcare sector, focusing on stocks such as Alcon, Roche Holding AG, and Sanofi. According to TipRanks, Evans has an average return of 0.4% and a 55.15% success rate on recommended stocks.
Currently, the analyst consensus on Alcon is a Strong Buy with an average price target of $96.38.
The company has a one-year high of $89.32 and a one-year low of $69.21. Currently, Alcon has an average volume of 933.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alcon (ALC) Company Description:
Alcon Inc. is a medical company which is specialized in eye care products. The company develops, manufactures, distributes, and sells technologies and devices for cataract, retinal, refractive surgery, as well as contact lenses and lens care products.
